Tofacitinib Equal to Etanercept in Psoriasis, but only at 10 mg bid Dose Save

A 12-week, phase III, non-inferiority, randomized clinical trial of tofacitinib, etanercept or placebo was conducted in 1106 patients with plaque psoriasis. At week 12, PASI-75 responses were seen in 39·5% of the tofacitinib 5 mg group, 63·6% of the tofacitinib 10 mg group, 58·8% of the etanercept group, and 5·6% of the placebo group. In patients with moderate-to-severe plaque psoriasis, the 10 mg twice daily dose of tofacitinib was non-inferior to etanercept and was superior to placebo; but the 5 mg twice daily dose was inferior to etanercept 50 mg twice weekly.